Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Expert interview on NTDs – part 3 - 24/09/2019 Curevac_Franz-Werner_Haas_.png

    Neglected tropical diseases – Franz-Werner Haas: the role of technology and pharmaceutical companies

    Neglected tropical diseases (NTDs) are poverty-related infectious diseases that suffer from scant attention in terms of research or control. NTDs exist in the shadow of the "big three": malaria, tuberculosis and HIV/AIDS. They affect many people living in poverty in the emerging and developing countries of the tropics and subtropics. Active control can only be achieved when people with NTDs are treated effectively and given information…

    https://www.gesundheitsindustrie-bw.de/en/article/news/vernachlaessigte-tropenkrankheiten-franz-werner-haas-die-rolle-von-technologie-und-pharmaunternehmen
  • Expert interview - 16/01/2019 Photo of Holger Mettler

    Cybersecurity is an important issue for the pharmaceutical industry

    In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cybersecurity-is-an-important-issue-for-the-pharmaceutical-industry
  • Expert interview - 17/10/2018 Porträtfoto von Dr. Ralf Schumacher

    Biologicals are becoming increasingly important to Boehringer Ingelheim

    Biopharmaceuticals are playing an increasingly important role in Boehringer Ingelheim’s development pipeline. Visible evidence of this is the company’s Biologicals Development Centre (BDC) that is currently being constructed in Boehringer Ingelheim’s Biberach plant and will bring the company’s process development under one roof by early 2020. Walter Pytlik from BIOPRO talked with Dr. Ing. Ralf Schumacher about the new centre.

    https://www.gesundheitsindustrie-bw.de/en/article/news/biologicals-are-becoming-increasingly-important-to-boehringer-ingelheim
  • Expert interview - 26/06/2018 Photo of Dr. med. Dr. rer. nat. Saskia Biskup.

    Genome analyses: "Germany lags behind dramatically"

    Around 6,000 genetic diseases can be diagnosed using genetic tests. Genetic testing enables the accurate identification of diseases especially when symptoms are unclear, and also allows statements to be made about disease progression. However, restrictive regulations considerably hinder the use of genetic diagnostics. BIOPRO spoke with Dr. Dr. Saskia Biskup, a human genetics specialist and co-founder of the Tübingen-based company CeGaT.

    https://www.gesundheitsindustrie-bw.de/en/article/news/genome-analyses-germany-lags-behind-dramatically
  • Big Data - 13/03/2018 Viegas-User-Activity-on-Wikipedia.png

    “More data does not automatically imply more knowledge“

    In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
  • Article - 14/08/2017 The two company founders in the laboratory holding reaction vessels.

    Saskia Biskup – towards precision medicine

    Therapeutic success can only be achieved when diagnoses are as precise as possible. Nowadays, genetic analyses can make precise diagnoses for many diseases. And thanks to high-throughput technology, results are available to patients very quickly. Dr. Dr. Saskia Biskup recognised the importance of precision medicine many years ago and went on to found CeGaT GmbH, a company that combines human genetics with high-throughput sequencing. Three…

    https://www.gesundheitsindustrie-bw.de/en/article/news/saskia-biskup-towards-precision-medicine
  • Expert interview - 02/08/2017 Photo of Michael Weißer.

    Innovative diagnosis and treatment methods – regulation of their reimbursement in the German healthcare sector

    The German healthcare cost reimbursement system differentiates between in- and outpatient medical products. In an interview with Caroline Ref and Jasmin Dabrowski from BIOPRO Baden-Württemberg, Michael Weißer, Chief Operating Officer of AiM GmbH in Lörrach, gives interesting insights into the reimbursement of medical care products, in particular with regard to the introduction of new and innovative diagnosis and treatment methods.

    https://www.gesundheitsindustrie-bw.de/en/article/news/innovative-diagnosis-and-treatment-methods-regulation-of-their-reimbursement-in-the-german-healthcare-sector
  • Article - 19/04/2017 View of a laboratory work place with a broad range of laboratory utensils in which a person (on the left, wearing a white lab coat) is working with frozen samples.

    Are start-ups a matter for the boss? A professor’s thoughts on university spin-offs

    Research work and entrepreneurship are by no means mutually exclusive. There are numerous successful university spin-offs in the life sciences sector that prove this only too well. However, the road from a good idea to a commercially successful company can be long and arduous. Those who benefit from the support of their boss from the outset can consider themselves extremely fortunate. Prof. Dr. Hans-Georg Rammensee talks about his experience with…

    https://www.gesundheitsindustrie-bw.de/en/article/news/are-start-ups-a-matter-for-the-boss-a-professors-thoughts-on-university-spin-offs
  • Article - 23/02/2017 Photo showing the two CEOs, Dr. Frank Mathias and Michael Scholl.

    Rentschler places formulation on biopharmaceuticals production agenda with LEUKOCARE alliance

    On February 2, 2017, Rentschler Biotechnologie and LEUKOCARE announced a strategic alliance in which LEUKOCARE will become the exclusive formulation developer for the Laupheim-based contract manufacturer. Rentschler will acquire a 10% stake in LEUKOCARE, a biotech company established in 2003 and headquartered in Martinsried. On behalf of BIOPRO, Walter Pytlik spoke with the two CEOs, Rentschler’s Dr. Frank Mathias and LEUKOCARE’s Michael Scholl…

    https://www.gesundheitsindustrie-bw.de/en/article/news/rentschler-places-formulation-on-biopharmaceuticals-production-agenda-with-leukocare-alliance
  • Expert interview - 14/11/2016 The photo shows a green plant.

    The great untapped potential of herbal medicines

    Baden-Württemberg is home to a large number of companies that produce herbal medicines, i.e. preparations made from plant extracts rather than pure compounds. In an interview with Dr. Ariane Pott from BIOPRO Baden-Württemberg, Professor Dr. Michael Wink, Director of the Institute of Pharmacy and Molecular Biotechnology at the University of Heidelberg, explains how these special extracts are placed on the market and how they differ from medicines…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-great-untapped-potential-of-herbal-medicines
  • Article - 18/01/2016 The photo shows two blister packs with tablets.

    New approaches in the life sciences industry: innovative strategies for courageous companies

    For many years, the pharmaceutical industry has been investing increasing amounts of money in the development of new products. Dr. Friedemann Taut, a specialist in anaesthesia, intensive care, emergency medicine and clinical pharmacology as well as founder and managing director of Taut Science & Service Ltd. a consultanca for Medical Device and Drug Development, explains in the following interview why small- and mid-sized companies can stay a…

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-avenues-in-the-life-sciences-industry-innovative-strategies-for-brave-companies
  • Article - 17/08/2015 Hugo_de_Wit.jpg

    Cellca geared for further growth following acquisition by Sartorius

    Sartorius Stedim Biotech (SSB), a leading international supplier to the pharmaceutical and biotechnology industries, acquired Laupheim-based Cellca GmbH on 1st July 2015. Walter Pytlik talked to Cellca CEO Hugo de Wit, who has been at the helm of the company since 2010, the first two years jointly with Dr. Aziz Cayli, about the background to the change of ownership and the consequences it will have.

    https://www.gesundheitsindustrie-bw.de/en/article/news/cellca-geared-for-further-growth-following-acquisition-by-sartorius
  • Part 2 - 06/10/2014

    Expert interview: How are the prices of innovative diagnostic and medical devices determined?

    While there are specific regulations in Germany for the reimbursement of medicines, funding for molecular diagnostics products is complex and virtually non-existent. There is hardly any medical insurance cover for medical devices, which therefore tend to be sold on the open market. The question therefore arises as to how a reasonable price can be determined for innovative diagnostic methods and tools. In the second part of the interview conducted…

    https://www.gesundheitsindustrie-bw.de/en/article/news/expert-interview-how-are-the-prices-of-innovative-diagnostic-and-medical-devices-determined
  • Part 1 - 22/09/2014 The photo shows different tablet packages and an open wallet mit coins and banknotes.<br />

    Expert interview: How are the prices of new pharmaceuticals determined?

    Healthcare in Germany is quite good. Pharmaceutical and biotechnology companies carry out research in order to improve it further. The question is, how can a fair price for innovative drugs be determined? BIOPRO Baden-Württemberg GmbH has talked to Dr. Manfred Caeser, a specialist in pricing and reimbursement at LSCN Ltd.

    https://www.gesundheitsindustrie-bw.de/en/article/news/expert-interview-how-are-the-prices-of-new-pharmaceuticals-determined
  • Article - 24/06/2013 19893_de.jpg

    Cloned human beings are not to be feared

    An international team of scientists led by Dr. Shoukhrat Mitalipov at the Oregon Health & Science University, USA, succeeded for the first time ever in cloning human embryonic stem cells by somatic cell nuclear transfer. This breakthrough raises questions about the potentials and dangers of creating human stem cells by cloning. Prof. Dr. Marcel Leist from the University of Konstanz, who uses human embryonic stem cells for his research, gives…

    https://www.gesundheitsindustrie-bw.de/en/article/news/cloned-human-beings-are-not-to-be-feared
  • Press release - 18/03/2013 19373_de.jpg

    Med Cell Europe AG: medicine from a patient’s own adipose tissue

    Med Cell Europe AG, which is headquartered in Münchwilen, Switzerland, and a member of the BioLAGO bioregion, is the only private stem cell bank in Europe that isolates adult stem cells from customers’ adipose tissue. The biotech company, which was founded in 2010, is also active in research. The focus, amongst other things, is on the transformation of stem cells into insulin-producing cells and cytotoxicity tests to explore potential damage to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/med-cell-europe-ag-medicine-from-a-patient-s-own-adipose-tissue
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search